Internal Reference Number: FOI_8687
Date Request Received: 03/06/2025 00:00:00
Date Request Replied To: 26/06/2025 00:00:00
This response was sent via: By Email
Request Summary: Oncology Breast Cancer
Request Category: Researcher
| Question Number 1: I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following questions How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel • Atezolizumab • Capivasertib • Capecitabine as a single agent • Carboplatin + Paclitaxel • Elacestrant • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Palbociclib + Fulvestrant • Parp Inhibitors (Olaparib/Talazoparib) • Pembrolizumab Monotherapy • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Pembrolizumab • Carboplatin + Paclitaxel + Pembrolizumab • Pertuzumab (Perteja) + Trastuzumab (Herceptin) • Phesgo (Pertuzumab + Trastuzumab in a single injection) • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Trastuzumab deruxtecan (Enhertu) • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel • Trastuzumab emtansine (Kadcyla) • Any other active systemic anti-cancer therapy • Aromatase Inhibitor as a single agent | |
| Answer To Question 1: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) - 30 • Abemaciclib + Fulvestrant - 6 • Alpelisib + Fulvestrant - <5 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide - <5 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel - 0 • Atezolizumab - 0 • Capivasertib - <5 • Capecitabine as a single agent - 10 • Carboplatin + Paclitaxel - <5 • Elacestrant - <5 • Eribulin as a single agent or in combination - <5 • Everolimus + Exemestane - <5 • Fulvestrant as a single agent - 0 • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) - 25 • Palbociclib + Fulvestrant - <5 • Parp Inhibitors (Olaparib/Talazoparib) - 0 • Pembrolizumab Monotherapy - <5 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Pembrolizumab - <5 • Carboplatin + Paclitaxel + Pembrolizumab - 0 • Pertuzumab (Perteja) + Trastuzumab (Herceptin) - <5 • Phesgo (Pertuzumab + Trastuzumab in a single injection) - 21 • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) - 17 • Ribociclib + Fulvestrant - <5 • Sacituzumab Govitecan - 7 • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent - <5 • Trastuzumab deruxtecan (Enhertu) - 5 • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel - 11 • Trastuzumab emtansine (Kadcyla) - <5 • Any other active systemic anti-cancer therapy - 13 • Aromatase Inhibitor as a single agent - can’t answer as single agent not prescribed on Aria and patients would get from the GP. | |
| Question Number 2: How many patients have been treated for metastatic breast cancer in the past 3 months with the following systemic anti-cancer therapies: • Phesgo (Pertuzumab + Trastuzumab in a single injection) • Pertuzumab (Perteja) + Trastuzumab (Herceptin) • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel • Trastuzumab deruxtecan (Enhertu) • Trastuzumab emtansine (Kadcyla) • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Ribociclib + Fulvestrant • Capecitabine as a single agent • Carboplatin + Paclitaxel • Carboplatin + Paclitaxel + Pembrolizumab | |
| Answer To Question 2: • Phesgo (Pertuzumab + Trastuzumab in a single injection) - 12 • Pertuzumab (Perteja) + Trastuzumab (Herceptin) - <5 • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel - 5 • Trastuzumab deruxtecan (Enhertu) - 5 • Trastuzumab emtansine (Kadcyla) - 0 • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) - 6 • Abemaciclib + Fulvestrant - 6 • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) - 16 • Ribociclib + Fulvestrant - <5 • Capecitabine as a single agent - 11 • Carboplatin + Paclitaxel - 0 • Carboplatin + Paclitaxel + Pembrolizumab - 0 | |
| Question Number 3: Does your trust participate in any Clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part. | |
| Answer To Question 3: The answers to Q3 are in the attached document. To accompany this answer to question 3 please also see the documents listed below:  FOI 8687 - Q3.pdf | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
